optum acquir diplomat
acquisit discount friday close monday open
announc pbm segment optumrx would acquir specialti pharmacy/pbm
diplomat pharmaci discount dplo friday close price philip
hagerman co-found certain person entiti affili mr hagerman
approx outstand common stock dplo agre tender
share connect offer believ offer price discount reflect
oper challeng recent busi loss diplomat accord drug channel
institut optumrx diplomat repres combin specialti pharmaci
market acquisit give access limit distribut drug dplo
infus busi transact unanim approv board director
diplomat accord letter brian griffin ceo dplo board forese
potenti transact close earli
immedi impact like minim estim financi effect
acquisit minim deal involv cash tender offer well
unh assumpt dplo outstand debt impli market cap mln along
net debt mln
deal align focu specialti market investor day
highlight given custom usual coverag term
limit distribut drug formulari addit compani note
effect captur new ldd come market optumrx continu
focu specialti medicin particularli infus abil treat diseas
compani made invest acquisit avella year ago
allow penetr oncolog ldd pbm break-out session
investor day optumrx ceo john princ highlight specialti market key
focu area specialti infus medic drive cost
compani also point drug infus hopd cost done
home physician offic current optumrx clinician across countri
alreadi serv peopl in-hom infus busi
background dplo sale earn dplo announc compani
review strateg altern includ limit sale merger compani
continu pursu value-enhanc initi stand-alone busi capit structur
chang sale disposit asset addit dplo amend certain
financi perform coven relat credit facil lender
earn compani announc effect dplo longer particip
signific group special retail network one largest payer addit
dplo lower adj ebitda outlook mln mln previous
includ go concern disclosur file
updat dplo price target updat tp vs previous reflect
deal price reflect vs previous ebitda estimate
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
updat dplo price target updat tp vs previous reflect
deal price reflect vs previous ebitda estimate
price
valuat metric
number share
 close
chang work capit
flow oper
free cash-flow firm
flow invest
issuanc retir debt
cash-flow financ activ
effect exchang rate
chang net cash/debt
net debt start
chang net debt
net debt end
intang asset goodwil
total liabil equiti
share wtd average
price book
roe stated-return
net debt ebitda
 close
compani mention price
 rice certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
